Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use

Journal of Analytical Toxicology

Volumn 34, Issue 8, 2010, Pages 444-449

  De Priest, Anne ^a   Heltsley, Rebecca ^a   Black, David L ^a,b   Cawthon, Beverly ^a   Robert, Tim ^a   Moser, Frank ^a   Caplan, Yale H ^c   Cone, Edward J ^d  

^a Aegis Sciences Corporation   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c National Scientific Services   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; BUPRENORPHINE; DEXTROPROPOXYPHENE; DRUG METABOLITE; FENTANYL; METHADONE; NORBUPRENORPHINE; NORFENTANYL; NORPETHIDINE; NORPROPOXYPHENE; OPIATE; PETHIDINE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC PAIN; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; OPIATE ADDICTION; PRESCRIPTION; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 79954615172     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/34.8.444     Document Type: Article

References (40)

1. N.P. Katz, E.H. Adams, J.C. Benneyan, H.G. Birnbaum, S.H. Budman, R.W. Buzzeo, D.B. Carr, T.J. Cicero, D. Gourlay, J.A. Inciardi, D.E. Joranson, J. Kesslick, and S.D. Lande. Foundations of opioid risk management. Clin. J. Pain 23: 103-118 (2007).
2. S.E. McCabe, C.J. Teter, and C.J. Boyd. Medical use, illicit use, and diversion of abusable prescription drugs. J. Am. Coll. Health 54: 269-278 (2006).
3. D.A. Fishbain, R.B. Cutler, H.L. Rosomoff, and R.S. Rosomoff. Validity of self-reported drug use in chronic pain patients. Clin. J. Pain 15: 184-191 (1999).
4. N.P. Katz, S. Sherburne, M. Beach, R.J. Rose, J.Vielguth, J. Bradley, and G.J. Fanciullo. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth. Analg. 97: 1097-1102 (2003).
5. H.A. Heit and D.L. Gourlay. Urine drug testing in pain medicine. J. Pain Symptom Manage. 27: 260-267 (2004).
6. E. Michna, R.N. Jamison, L.D. Pham, E.L. Ross, D. Janfaza, S.S. Nedeljkovic, S. Narang, D. Palombi, and A.D.Wasan. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin. J. Pain 23: 173-179 (2007).
7. J. Feng, L. Wang, I. Dai, T. Harmon, and J.T. Bernert. Simultaneous determination of multiple drugs of abuse and relevant metabolites in urine by LC-MS-MS. J. Anal. Toxicol. 31: 359-368 (2007).
8. R. Coles, M.M. Kushnir, G.J. Nelson, G.A. McMillin, and F.M. Urry. Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC-MS-MS. J. Anal. Toxicol. 31: 1-14 (2007).
9. E. Gustavsson, M. Andersson, N. Stephanson, and O. Beck. Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing. J. Mass Spectrom. 42: 881-889 (2007).
10. H.H. Maurer. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal. Bioanal. Chem. 388: 1315-1325 (2007).
11. R.L. Fitzgerald, J.D. Rivera, and D.A. Herold. Broad spectrum drug identification directly from urine, using liquid chromatography- tandem mass spectrometry. Clin. Chem. 45: 1224-1234 (1999).
12. M. Concheiro, A. de Castro, O. Quintela, A. Cruz, and M. Lopez-Rivadulla. Determination of illicit and medicinal drugs and their metabolites in oral fluid and preserved oral fluid by liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 391: 2329-2338 (2008).
13. M. Wood, M. Laloup, M.M. Ramirez Fernandez, K.M. Jenkins, M.S. Young, J.G. Ramaekers, G. De Boeck, and N. Samyn. Quantitative analysis of multiple illicit drugs in preserved oral fluid by solid-phase extraction and liquid chromatography-tandem mass spectrometry. Forensic Sci. Int. 150: 227-238 (2005).
14. F. Musshoff, J. Trafkowski, U. Kuepper, and B. Madea. An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites. J. Mass Spectrom. 41: 633-640 (2006).
15. M. Gergov, P. Nokua, E. Vuori, and I. Ojanperä. Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography-tandem mass spectrometry. Forensic Sci. Int. 186: 36-43 (2009).
16. R. Heltsley, A. Zichterman, D.L. Black, B. Cawthon, T. Robert, F. Moser, Y.H. Caplan, and E.J. Cone. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. J. Anal. Toxicol. 34: 32-38 (2010).
17. E.J. Cone, Y.H. Caplan, D.L. Black, T. Robert, and F. Moser. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J. Anal. Toxicol. 32: 530-543 (2008).
18. R.E. Johnson, P.J. Fudala, and R. Payne. Buprenorphine: considerations for pain management. J. Pain Symptom Manage. 29: 297-326 (2005).
19. A. Elkader and B. Sproule. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 44: 661-680 (2005).
20. P. Huang, G.B. Kehner, A. Cowan, and L.Y. Liu-Chen. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 297: 688-695 (2001).
21. E.J. Cone, C.W. Gorodetzky, D. Yousefnejad, W.F. Buchwald, and R.E. Johnson. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12: 577-581 (1984).
22. R. Kronstrand, T.G. Selden, and M. Josefsson. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 27: 464-470 (2003).
23. J.J. Kuhlman, S. Lalani, J. Magluilo, B. Levine, W.D. Darwin, R.E. Johnson, and E.J. Cone. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J. Anal. Toxicol. 20: 369-378 (1996).
24. J.J. Kuhlman, B. Levine, R.E. Johnson, P.J. Fudala, and E.J. Cone. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93(4): 549-559 (1998).
25. D.A. McClain and C.C. Hug, Jr. Intravenous fentanyl kinetics. Clin. Pharmacol. Ther. 28: 106-114 (1980).
26. R.B. Labroo, M.F. Paine, K.E. Thummel, and E.D. Kharasch. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab. Dispos. 25: 1072-1080 (1997).
27. T.I. Saari, K. Laine, M. Neuvonen, P.J. Neuvonen, and K.T. Olkkola. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur. J. Clin. Pharmacol. 64: 25-30 (2008).
28. J.H. Silverstein, M.F. Rieders, M. McMullin, S. Schulman, and K. Zahl. An analysis of the duration of fentanyl and its metabolites in urine and saliva. Anesth. Analg. 76: 618-621 (1993).
29. A. Poklis and R. Backer. Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches. J. Anal. Toxicol. 28: 422-425 (2004).
30. R.F. Clark, E.M. Wei, and P.O. Anderson. Meperidine: therapeutic use and toxicity. J. Emerg. Med. 13: 797-802 (1995).
31. D.E. Joranson, K.M. Ryan, A.M. Gilson, and J.L. Dahl. Trends in medical use and abuse of opioid analgesics. J. Am. Med. Assoc. 283: 1710-1714 (2000).
32. J. Ramirez, F. Innocenti, E.G. Schuetz, D.A. Flockhart, M.V. Relling, R. Santucci, and M.J. Ratain. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab. Dispos. 32: 930-936 (2004).
33. I.T. Houghton, K. Chan, Y.C. Wong, C.S. Aun, O.W. Lau, and D.M. Lowe. Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. Methods Fund. Exp. Clin. Pharmacol. 14: 451-458 (1992).
34. P.L. Manfredi and R.W. Houde. Prescribing methadone, a unique analgesic. J. Support. Oncol. 1: 216-220 (2003).
35. R.A. Totah, K.E. Allen, P. Sheffels, D. Whittington, and E.D. Kharasch. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J. Pharmacol. Exp. Ther. 321: 389-399 (2007).
36. R.A. Totah, P. Sheffels, T. Roberts, D. Whittington, K. Thummel, and E.D. Kharasch. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108: 363-374 (2008).
37. E.D. Kharasch, C. Hoffer, D.Whittington, and P. Sheffels. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76: 250-269 (2004).
38. A.A. Somogyi, A. Menelaou, and S.V. Fullston. CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica 34: 875-887 (2004).
39. R.J. Flanagan, A. Johnston, A.S. White, and P. Crome. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage. Br. J. Clin. Pharmacol. 28: 463-469 (1989).
40. C. Wu, C.H. Fry, and J. Henry. The mode of action of several opioids on cardiac muscle. Exp. Physiol. 82: 261-272 (1997).